A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel With Bevacizumab as First-Line Therapy in Patients With FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TEACO
- 30 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2009 Planned end date changed from 1 Aug 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 25 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.